Who owns Celldex Therapeutics?

Top Holders and Investors of CLDX Stock

Find out what company owns Celldex Therapeutics, who bought CLDX this quarter, and who sold shares of CLDX stock?

Fund or Company Name Number of Shares Valued At As Of
Meditor 420846 $1.13M Jun 2019
Benchmark Capital Advisors 32600 $5868 Dec 2018
Horizon Kinetics 26335 $0 Dec 2018

Who sold Celldex Therapeutics?

Fund Name Date Sold Shares Held Valued At
KLP Enterprises Dec. 31, 2018 6.87M $1.37M
Vanguard Dec. 31, 2018 6.26M $1.25M
Two Sigma Investments Dec. 31, 2018 1.74M $348215
Deutsche Bank Aktiengesellschaft Dec. 31, 2018 1.27M $0
Frigate Ventures Dec. 31, 2018 1.23M $245968
Geode Capital Management Dec. 31, 2018 1.12M $223982
Two Sigma Advisers Dec. 31, 2018 634750 $126950
QS Investors Dec. 31, 2018 386530 $77306
Millennium Management Dec. 31, 2018 379382 $75876
Telemetry Investments Dec. 31, 2018 348501 $69700
CalPERS Dec. 31, 2018 180400 $36080
Inves Dec. 31, 2018 173172 $34634
State Street Corporation Dec. 31, 2018 134640 $26928
Susquehanna International Dec. 31, 2018 121204 $24240
Hambrecht & Quist Capital Management Dec. 31, 2018 105800 $21160
T. Rowe Price Associates Dec. 31, 2018 105402 $21080
Morgan Stanley Dec. 31, 2018 86539 $0
Hrt Financial Dec. 31, 2018 77682 $14759
UBS Group AG Dec. 31, 2018 68194 $21822
Tudor Investment Corporation Dec. 31, 2018 65439 $13087
Macquarie Dec. 31, 2018 52000 $9880
Commonwealth Equity Services Dec. 31, 2018 19898 $2984
United Services Automobile Association Dec. 31, 2018 14541 $3053
Nordea Investment Management Ab Dec. 31, 2018 10000 $2000
Ladenburg Thalmann Financial Services Dec. 31, 2018 7400 $1036
Rehmann Capital Advisory Dec. 31, 2018 5426 $1073
Financial Architects Dec. 31, 2018 2245 $0
Bank of America Corporation Dec. 31, 2018 1445 $0
IFP Advisors Dec. 31, 2018 900 $0
Royal Bank of Canada Dec. 31, 2018 630 $0
Barclays Dec. 31, 2018 78 $0

Funds that own CLDX also own: